An exciting study..a drug for depression helps Corona patients

08:21 AM

Thursday 28 October 2021

Cairo – Masrawy:

A study published Thursday showed that the use of the antidepressant fluvoxamine to treat severely ill COVID-19 patients may reduce by a third of their need for long-term hospitalization.

The authors of the study said, according to “Sky News”, that “this research can help enhance protection from severe (Covid 19) symptoms or even death, at low cost, in countries that suffer from a lack of vaccines.”

Fluvoxamine is used to treat psychiatric and mental illnesses such as depression and obsessive-compulsive disorder, and was selected for trials because of its anti-inflammatory properties.

Many of the problems resulting from infection with the Corona virus are caused by swelling due to the excessive reaction of the immune system against infection.
Researchers from North and South America published in the journal “The Lance Public Health” the results of experiments in which 1,500 people with “Covid 19” participated in Brazil, one of the countries in the world most affected by the epidemic.

Of the 741 people who received fluvoxamine, 79 patients, or only 10 percent, needed to stay in hospital to receive treatment.

The researchers indicated that giving the drug led to a relative decrease in the need for hospitalization by 32 percent.

“(Covid 19) continues to pose a risk to people in countries with low resources or with limited vaccines,” said Edward Mills of McMaster University and one of the experiments working on the trials.


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.